{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:38:52Z","timestamp":1793090332666,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jad.2026.122647","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:13:25Z","timestamp":1792595605000},"page":"122647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Suicidality during intranasal (es)ketamine treatment: A retrospective cohort study"],"prefix":"10.1016","volume":"417","author":[{"given":"Yamina","family":"Ehrt-Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Olbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ferrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2026.122647_bb0005","article-title":"Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial","author":"Abbar","year":"2022","journal-title":"BMJ (Clin. Res. Ed.)"},{"issue":"1","key":"10.1016\/j.jad.2026.122647_bb0010","article-title":"Ketamine therapy in complex cases: a cautionary tale of exacerbated personality traits and the crucial role of comprehensive follow-up and psychosocial interventions","volume":"2024","author":"Ahuja","year":"2024","journal-title":"Case Rep. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2026.122647_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ph18050702","article-title":"Safety profile and suicidality associated with the use of esketamine in the treatment of major depressive disorder in European countries: an EudraVigilance database analysis","volume":"18","author":"Ammendolia","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jad.2026.122647_bb0020","series-title":"A Comparison Between Patient-Rated Scale (BDI) with Clinician-Rated Scale (MADRS) in Major Depressive Disorder","first-page":"6","volume":"29","author":"Ashari","year":"2022"},{"key":"10.1016\/j.jad.2026.122647_bb0025","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122647_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.598434","article-title":"New methods for assessing rapid changes in suicide risk","volume":"12","author":"Ballard","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpsychires.2015.06.003","article-title":"Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant","volume":"68","author":"Ballard","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122647_bb0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jad.2018.07.077","article-title":"Characterizing the course of suicidal ideation response to ketamine","volume":"241","author":"Ballard","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jad.2026.122647_bb0045","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of Beck depression inventories-IA and-II in psychiatric outpatients","volume":"67","author":"Beck","year":"1996","journal-title":"J. Pers. Assess."},{"issue":"31","key":"10.1016\/j.jad.2026.122647_bb0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mhw.32471","article-title":"FDA approves esketamine treatment for MDD, suicidal ideation","volume":"30","author":"Canady","year":"2020","journal-title":"Ment. Heal. Wkly."},{"issue":"7","key":"10.1016\/j.jad.2026.122647_bb0055","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0060","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/NDT.S401032","article-title":"Acute effects of intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine on suicidal ideation: a systematic review and meta-analysis","volume":"19","author":"Chen","year":"2023","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2026.122647_bb0065","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2019.19050508","article-title":"All suicidal ideation is not created equal: two cases of suicide attempts during maintenance ketamine treatment","author":"Cusin","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.genhosppsych.2023.01.007","article-title":"Risk of suicide attempt repetition after an index attempt: a systematic review and meta-analysis","volume":"81","author":"de la Torre-Luque","year":"2023","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2026.121257","article-title":"Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: evidence from real-world studies","volume":"401","author":"de Oliveira Lapa","year":"2026","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.jad.2026.122647_bb0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/00048674211043455","article-title":"Suicide mortality after a nonfatal suicide attempt: a systematic review and meta-analysis","volume":"56","author":"Demesmaeker","year":"2022","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.122647_bb0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40360-025-00992-2","article-title":"The post-marketing safety of esketamine among older adults (\u226565): an real-world pharmacovigilance study","volume":"26","author":"Deng","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.jad.2026.122647_bb0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jpsychires.2021.02.058","article-title":"The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: a systematic review","volume":"137","author":"Di Vincenzo","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122647_bb0095","series-title":"Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial (SSRN Scholarly Paper Nr. 3367057)","author":"Domany","year":"2019"},{"key":"10.1016\/j.jad.2026.122647_bb0100","article-title":"Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis","author":"Fountoulakis","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2026.122647_bb2000","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jpsychires.2014.09.011","article-title":"Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and anxiety severity in patients with major depressive disorder or bipolar disorder","volume":"60","author":"Gao","year":"2015","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jad.2026.122647_bb0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother. Psychosom."},{"issue":"12","key":"10.1016\/j.jad.2026.122647_bb0115","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.4088\/JCP.14m09391","article-title":"The predictive validity of the beck depression inventory suicide item","volume":"76","author":"Green","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0125","article-title":"The rapid anti-suicidal ideation effect of ketamine: a systematic review","volume":"152","author":"Hochschild","year":"2021","journal-title":"Prev. Med. Suicide Prev."},{"issue":"1","key":"10.1016\/j.jad.2026.122647_bb2005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.jad.2026.122647_bb0130","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/chi.0b013e3180cc2575","article-title":"A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children","volume":"46","author":"Jain","year":"2007","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.122647_bb0135","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1186\/s12888-024-06203-2","article-title":"Ketamine and chronic treatment-resistant depression: real-world practice and after relapse","volume":"24","author":"Jobnah","year":"2024","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231151327","article-title":"Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review","volume":"13","author":"Jollant","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122647_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2023.11.043","article-title":"Clinical predictive factors and trajectories of suicidal remission over 6 weeks following intravenous ketamine for suicidal ideation","volume":"347","author":"Jollant","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122647_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2023.103678","article-title":"The efficacy of oral ketamine in severely depressed patients at high risk of suicide","volume":"86","author":"Kaur","year":"2023","journal-title":"Asian J. Psychiatr."},{"issue":"3","key":"10.1016\/j.jad.2026.122647_bb0155","article-title":"A global population-based study on the association between ketamine and esketamine with suicidality using WHO VigiBase","volume":"86","author":"Kwan","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0160","article-title":"Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis","author":"Li","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jad.2026.122647_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-026-04032-3","article-title":"Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data","volume":"16","author":"Liu","year":"2026","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0175","article-title":"Gender differences in suicidal and self-harming responses to esketamine: a real-world retrospective study","author":"Martiadis","year":"2025","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.jad.2026.122647_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/jcm15041629","article-title":"Integrating psychiatric, psychotherapeutic, and nursing care in intranasal esketamine for treatment-resistant depression","volume":"15","author":"Martiadis","year":"2026","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jad.2026.122647_bb0185","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122647_bb0190","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jad.2021.12.097","article-title":"A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings","volume":"301","author":"McInnes","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jad.2026.122647_bb0195","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb2010","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2026.122647_bb0200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.jad.2026.122647_bb0205","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/0269881113486718","article-title":"Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder","volume":"27","author":"Niciu","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122647_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115833","article-title":"Association of clinical characteristics, depression remission and suicide risk with discrepancies between self- and clinician-rated suicidal ideation: two large naturalistic cohorts of outpatients with depression","volume":"335","author":"Nobile","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2026.122647_bb0215","article-title":"Paradoxical depressive response to intranasal esketamine in treatment-resistant depression: a case series","volume":"25","author":"Ontiveros-S\u00e1nchez de la Barquera","year":"2024","journal-title":"Am. J. Case Rep."},{"issue":"1","key":"10.1016\/j.jad.2026.122647_bb0220","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41398-024-03033-4","article-title":"Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study","volume":"14","author":"Pan","year":"2024","journal-title":"Transl. Psychiatry"},{"issue":"7","key":"10.1016\/j.jad.2026.122647_bb0225","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.comppsych.2012.02.009","article-title":"A meta-analysis of the association between posttraumatic stress disorder and suicidality: the role of comorbid depression","volume":"53","author":"Panagioti","year":"2012","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2026.104983","article-title":"Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: a real-world longitudinal study of suicidal ideation and self-harm","volume":"120","author":"Raffone","year":"2026","journal-title":"Asian J. Psychiatr."},{"issue":"1","key":"10.1016\/j.jad.2026.122647_bb0235","article-title":"Completed suicides and intranasal esketamine therapy: a case report and case series","volume":"2","author":"Rayburn","year":"2023","journal-title":"Psychiatry Res. Case Rep."},{"issue":"1","key":"10.1016\/j.jad.2026.122647_bb2015","doi-asserted-by":"crossref","DOI":"10.1080\/20008066.2025.2609425","article-title":"Trauma re-experiencing episodes during esketamine treatment in patients with treatment-resistant depression and comorbid PTSD: a retrospective case series","volume":"17","author":"Roth\u00e4rmel","year":"2026","journal-title":"Eur. J. Psychotraumatol."},{"issue":"4","key":"10.1016\/j.jad.2026.122647_bb0240","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae017","article-title":"Acute dissociation and ketamine's antidepressant and anti-suicidal ideation effects in a midazolam-controlled trial","volume":"27","author":"Sajid","year":"2024","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2026.122647_bb0245","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1176\/appi.ajp.20240655","article-title":"Real-world safety of esketamine nasal spray: a comprehensive analysis almost 5 years after first approval","volume":"182","author":"Sanacora","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2026.122647_bb0250","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1176\/appi.ajp.2019.19040423","article-title":"A word to the wise about intranasal esketamine","volume":"176","author":"Schatzberg","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2026.122647_bb0260","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/00048674251374472","article-title":"Ketamine\/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: a systematic review of effectiveness","volume":"59","author":"Scott","year":"2025","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2026.122647_bb0255","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ijop.13125","article-title":"The social-cognitive clinician: on the implications of social cognitive theory for psychotherapy and assessment","volume":"59","author":"Scott","year":"2024","journal-title":"Int. J. Psychol."},{"issue":"9","key":"10.1016\/j.jad.2026.122647_bb0265","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1111\/bcp.15360","article-title":"Ketamine for suicidality: an umbrella review","volume":"88","author":"Shamabadi","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2026.122647_bb0270","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jad.2024.01.262","article-title":"Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine\/esketamine","volume":"351","author":"Singh","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.jad.2026.122647_bb0275","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-025-02955-4","article-title":"Integrating case reports into systematic reviews: methodological strategies and challenges","volume":"14","author":"Taha","year":"2025","journal-title":"Syst. Rev."},{"issue":"6","key":"10.1016\/j.jad.2026.122647_bb0280","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1503\/jpn.190073","article-title":"Ketamine for chronic depression: two cautionary tales","volume":"44","author":"Talbot","year":"2019","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.jad.2026.122647_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.120751","article-title":"The role of frontal EEG in predicting clinical response of major depressive disorder to intranasal ketamine and esketamine","volume":"395","author":"Trenado","year":"2026","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.jad.2026.122647_bb0290","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/15622975.2022.2031287","article-title":"Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder","volume":"23","author":"Vanicek","year":"2022","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2026.122368","article-title":"Discordant signals: how outcome measurement shapes interpretation of ketamine response in treatment-resistant depression","volume":"414","author":"Vazquez","year":"2026","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122647_bb0300","article-title":"Suicide versus accidental death by autoerotic asphyxiation in a patient receiving intravenous ketamine for depression","volume":"2022","author":"Weleff","year":"2022","journal-title":"Case Rep. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0305","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122647_bb0310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpsychires.2020.12.038","article-title":"The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis","volume":"134","author":"Xiong","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2026.122647_bb0315","article-title":"Comparing the adverse effects of ketamine and esketamine between genders using FAERS data","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.jad.2026.122647_bb0320","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jaac.2023.05.031","article-title":"Effect of repeated intravenous esketamine on adolescents with major depressive disorder and suicidal ideation: a randomized active-placebo-controlled trial","volume":"63","author":"Zhou","year":"2024","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726015016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726015016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:12:21Z","timestamp":1793088741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726015016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":67,"alternative-id":["S0165032726015016"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.122647","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suicidality during intranasal (es)ketamine treatment: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.122647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122647"}}